Abstract
AlloSCT from a HLA matched sibling donor is the preferred treatment in children with acquired SAA in children. Alternative donor HSCT gives inferior results, and has been reserved for patients lacking matched family donors and unresponsive to medical therapy. However, given the poor outcome of medical therapy in subsets of patients with SAA, the advent less toxic fludarabine (FLU)-based non-myeloablative (NMA) regimens (Chan et al, BMT, 2001), and our recent experience with UCBT (Styczynski/Cairo et al, BMT, 2004), we investigated a risk-adapted AlloSCT approach to 17 consecutive children with SAA with matched related or unrelated donors between 01/2001 and 08/2006.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
